Processing

Please wait...

Settings

Settings

Goto Application

1. WO1990012577 - TOPICAL ANTI-ANGIOGENIC AS HAIR GROWTH INHIBITORS

Publication Number WO/1990/012577
Publication Date 01.11.1990
International Application No. PCT/US1990/000812
International Filing Date 20.02.1990
Chapter 2 Demand Filed 09.10.1990
IPC
A61K 8/63 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
63Steroids; Derivatives thereof
A61K 31/57 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61K 31/58 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
A61Q 7/02 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
7Preparations for affecting hair growth
02Preparations for inhibiting or slowing hair growth
CPC
A61K 31/57
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61K 31/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
58containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 8/63
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
63Steroids; Derivatives thereof
A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61Q 7/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
7Preparations for affecting hair growth
02Preparations for inhibiting or slowing hair growth
Applicants
  • THE UPJOHN COMPANY [US]/[US] (AllExceptUS)
  • HOLLAND, J., Michael [US]/[US] (UsOnly)
  • LAKINGS, Duane, B. [US]/[US] (UsOnly)
Inventors
  • HOLLAND, J., Michael
  • LAKINGS, Duane, B.
Agents
  • CORNEGLIO, Donald, L.
  • PERRY, Robert, E.
Priority Data
339,83618.04.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TOPICAL ANTI-ANGIOGENIC AS HAIR GROWTH INHIBITORS
(FR) ANTI-ANGIOGENIQUE TOPIQUE A USAGE D'INHIBITEUR DE CROISSANCE CAPILLAIRE
Abstract
(EN)
A method of inhibiting hair growth in mammals which comprises the topical administration of a composition comprising an anti-angiogenic effective amount of an angiostatic compound of formula (I). The formula (I) compound is present in an amount of at least 1 mg/ml, preferably from about 1 mg/ml to about 10 mg/ml.
(FR)
Est décrit un procédé pour inhiber la croissance capillaire chez des mammifères, qui comporte l'administration topique d'une composition renfermant une quantité efficace anti-angiogénique d'un composé angiostatique de formule (I). Ce composé est présent dans une quantité d'au moins 1 mg/ml, de préférence comprise entre environ 1 mg/ml et environ 10 mg/ml.
Latest bibliographic data on file with the International Bureau